GlassScriptPhysician profile
Alicia Grady
NPI 1235113002
$5,463.73
in general payments reported to CMS, 2019-2025
28 companies · $565 in 2025
The $565 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,792 · 2020: $270 · 2021: $18.30 · 2023: $280 · 2024: $540 · 2025: $565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,362.15 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $657.01 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $506.95 | 2019-2025 | Evenity, Otezla, Repatha |
| Astellas Pharma US INC | $396.66 | 2019-2025 | Veozah |
| Lilly USA, LLC | $314.49 | 2019-2025 | Zepbound, Mounjaro |
| Novo Nordisk INC | $198.37 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $163.15 | 2019-2024 | |
| Phadia US INC. | $101.61 | 2019-2025 | Immunocap |
| Shield Therapeutics INC | $92.88 | 2023-2024 | |
| Glaxosmithkline, LLC. | $73.14 | 2019-2025 | Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.20 | 2019 | |
| Novartis Pharmaceuticals Corporation | $54.57 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.84 | 2025 | |
| Pfizer INC. | $47.79 | 2019-2023 | |
| Corcept Therapeutics | $42.28 | 2019-2025 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $39.15 | 2019 | |
| Allergan, INC. | $38.03 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $37.30 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $35.92 | 2019 | |
| Ironwood Pharmaceuticals, INC | $34.72 | 2019 | |
| Exact Sciences Corporation | $27.77 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $24.71 | 2019 | |
| Genentech USA, INC. | $23.95 | 2019 | |
| Paratek Pharmaceuticals, INC. | $22.04 | 2023 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.31 | 2023 | Xifaxan, Trulance |
| Sanofi Pasteur INC. | $14.88 | 2019 | |
| Phathom Pharmaceuticals, INC. | $14.11 | 2024 | Voquezna |
| Roche Diabetes Care, INC. | $13.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alicia Grady listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.